BIOTRONIK Announces Results of REPLACE Registry, the First and Largest Prospective Study of Device Replacement Includes All CRM Manufacturers

LAKE OSWEGO, Ore.--(BUSINESS WIRE)--BIOTRONIK, Inc. today announced the results from site preparation, antibiotic use, and infection sub-analysis from the REPLACE Registry. The results, based on analysis of 1,031 patients undergoing elective replacement of their implanted cardiac rhythm management (CRM) device, provides important insight on techniques for surgical site preparation and antibiotic use in device-replacement procedures.